Malignant Biliary Tract Neoplasm

subtype

Identifier: CI-CAN-00003139
Entity page: /cancer/malignant-biliary-tract-neoplasm ↗
Edges: 1,561

Neighbours: 19 genes4 variants24 drugs10 trials
Drawn: 57 of 57 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Malignant Biliary Tract Neoplasm approved for …APPROVED_FOR10 of 5
← approved for	Pembrolizumabmonoclonal_antibody	supports	FDA ORIG	Malignant Biliary Tract Neoplasm	1	Regulatory	openfda	graph →
← approved for	Durvalumabmonoclonal_antibody	supports	FDA ORIG

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

FGFR2 Fusion Infigratinib0 active / 5 trials
Curatedlevel Asensitivity· support 3civicObservedcohort frequency not yet available for FGFR2 in this cancerno approval record in this cancercontext: Cholangiocarcinoma
FGFR2 Fusion Infigratinib0 active / 5 trials
Curatedlevel Asensitivity· support 3civicObservedcohort frequency not yet available for FGFR2 in this cancerno approval record in this cancercontext: Cholangiocarcinoma
IDH1 R132 IvosidenibFDA US 2018-07-203 active / 6 trials
Curatedlevel Asensitivity· support 1civicObservedIDH1 altered in 21% (85 / 412 cases, largest of 3 cohorts)Regulatoryapproved for Cholangiocarcinomacontext: Cholangiocarcinoma
FGFR2 Fusion PemigatinibFDA US 2020-04-173 active / 10 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for FGFR2 in this cancerRegulatoryapproved for Cholangiocarcinoma (2 approval records)context: Cholangiolocellular Small Duct Intrahepatic Cholangiocarcinoma
FGFR2 Fusion PemigatinibFDA US 2020-04-173 active / 10 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for FGFR2 in this cancerRegulatoryapproved for Cholangiocarcinoma (2 approval records)context: Cholangiolocellular Small Duct Intrahepatic Cholangiocarcinoma
BRAF V600E DabrafenibFDA US 2013-05-29 · tumour-agnostic0 active / 0 trials
Curatedlevel Bsensitivity· support 4civicObservedBRAF altered in 6.3% (26 / 412 cases)Regulatoryapproved (2 approval records)context: Intrahepatic Cholangiocarcinoma, Malignant Biliary Tract Neoplasm, Cholangiocarcinoma
BRAF V600E TrametinibFDA US 2013-05-29 · tumour-agnostic0 active / 3 trials
Curatedlevel Bsensitivity· support 4civicObservedBRAF altered in 6.3% (26 / 412 cases)Regulatoryapproved (2 approval records)context: Intrahepatic Cholangiocarcinoma, Malignant Biliary Tract Neoplasm, Cholangiocarcinoma
ERBB2 Amplification Pertuzumab0 active / 0 trials
Curatedlevel Bsensitivity· support 2civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: Malignant Biliary Tract Neoplasm, Cholangiocarcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Malignant Biliary Tract Neoplasm predicts response to …PREDICTS_RESPONSE_TO6 of 6
in context · predicts response to	ERBB2 Amplificationamplification → predicts response to Trastuzumab	sensitivity	B	Malignant Biliary Tract Neoplasm	1	Curated	civic	graph →
in context · predicts response to	ERBB2 Amplificationamplification → predicts response to Pertuzumab	sensitivity	B	Malignant Biliary Tract Neoplasm	1	Curated	civic	graph →
in context · predicts response to	BRAF V600ESNV → predicts response to Dabrafenib	sensitivity	B	Malignant Biliary Tract Neoplasm	1	Curated	civic	graph →
in context · predicts response to	BRAF V600ESNV → predicts response to Trametinib	sensitivity	B	Malignant Biliary Tract Neoplasm	1	Curated	civic	graph →
in context · predicts response to	BRCA1 Mutationother → predicts response to Olaparib	sensitivity	B	Malignant Biliary Tract Neoplasm	1	Curated	civic	graph →
in context · predicts response to	BRCA2 Mutationother → predicts response to Olaparib	sensitivity	B	Malignant Biliary Tract Neoplasm	1	Curated	civic	graph →

Malignant Biliary Tract Neoplasm associated with …ASSOCIATED_WITH4 of 4
← associated with	ERBB2	supports	B	Malignant Biliary Tract Neoplasm	1	Curated	civic	graph →
← associated with	BRAF	supports	B	Malignant Biliary Tract Neoplasm	1	Curated	civic	graph →
← associated with	BRCA1	supports	B	Malignant Biliary Tract Neoplasm	1	Curated	civic	graph →
← associated with	BRCA2	supports	B	Malignant Biliary Tract Neoplasm	1	Curated	civic	graph →

Malignant Biliary Tract Neoplasm investigated for …INVESTIGATED_FOR5 of 5
← investigated for	Trastuzumabmonoclonal_antibody	supports	B	Malignant Biliary Tract Neoplasm	1	Curated	civic	graph →
← investigated for	Pertuzumabmonoclonal_antibody	supports	B	Malignant Biliary Tract Neoplasm	1	Curated	civic	graph →
← investigated for	Trametinibsmall_molecule	supports	B	Malignant Biliary Tract Neoplasm	1	Curated	civic	graph →
← investigated for	Dabrafenibsmall_molecule	supports	B	Malignant Biliary Tract Neoplasm	1	Curated	civic	graph →
← investigated for	Olaparibsmall_molecule	supports	B	Malignant Biliary Tract Neoplasm	1	Curated	civic	graph →

Malignant Biliary Tract Neoplasm altered in cohorts of …ALTERED_INderived15 of 140show all (up to 200)
← altered in cohorts of	HTR6 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	KLHDC7A 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MRTO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TAS1R2 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TMCO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AADACL3 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AADACL4 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ACTL8 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AHDC1 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AKR7A3 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ALDH4A1 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ALPL 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ARHGEF10L 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ASAP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ATP13A2 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →

Malignant Biliary Tract Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 122show all (up to 200)
→ investigated in trials for	Gemcitabinesmall molecule 137 trials (48 active) · roll-up of the cancer and its descendants	—	—	Malignant Biliary Tract Neoplasm	137	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 97 trials (44 active) · roll-up of the cancer and its descendants	—	—	Malignant Biliary Tract Neoplasm	97	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 53 trials (17 active) · roll-up of the cancer and its descendants	—	—	Malignant Biliary Tract Neoplasm	53	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal_antibody 50 trials (36 active) · roll-up of the cancer and its descendants	—	—	Malignant Biliary Tract Neoplasm	50	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 43 trials (16 active) · roll-up of the cancer and its descendants	—	—	Malignant Biliary Tract Neoplasm	43	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 43 trials (12 active) · roll-up of the cancer and its descendants	—	—	Malignant Biliary Tract Neoplasm	43	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal_antibody 40 trials (15 active) · roll-up of the cancer and its descendants	—	—	Malignant Biliary Tract Neoplasm	40	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenvatinibsmall molecule 31 trials (16 active) · roll-up of the cancer and its descendants	—	—	Malignant Biliary Tract Neoplasm	31	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 25 trials (8 active) · roll-up of the cancer and its descendants	—	—	Malignant Biliary Tract Neoplasm	25	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 23 trials (12 active) · roll-up of the cancer and its descendants	—	—	Malignant Biliary Tract Neoplasm	23	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 21 trials (5 active) · roll-up of the cancer and its descendants	—	—	Malignant Biliary Tract Neoplasm	21	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 18 trials (6 active) · roll-up of the cancer and its descendants	—	—	Malignant Biliary Tract Neoplasm	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 17 trials (6 active) · roll-up of the cancer and its descendants	—	—	Malignant Biliary Tract Neoplasm	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Adebrelimabmonoclonal antibody 12 trials (11 active) · roll-up of the cancer and its descendants	—	—	Malignant Biliary Tract Neoplasm	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Tislelizumabmonoclonal antibody 12 trials (8 active) · roll-up of the cancer and its descendants	—	—	Malignant Biliary Tract Neoplasm	12	Observed	clinicaltrials	graph →

Malignant Biliary Tract Neoplasm studied in …STUDIED_INderived10 of 1,279show all (up to 200)
→ studied in	NCT04645160Phase 1/Phase 2 · recruiting Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers · condition mapped ONTOLOGY_EXACT · 1,279 trials mapped (456 active)	—	—	Cholangiocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · condition mapped ONTOLOGY_EXACT · 1,279 trials mapped (456 active)	—	—	Cholangiocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05482893Phase 1/Phase 2 · recruiting Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) · condition mapped ALIAS · 1,279 trials mapped (456 active)	—	—	Malignant Biliary Tract Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05712356Phase 2 · completed A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 1,279 trials mapped (456 active)	—	—	Cholangiocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07221253Phase 3 · recruiting A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) · condition mapped ALIAS · 1,279 trials mapped (456 active)	—	—	Malignant Biliary Tract Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07277413Phase 1 · recruiting A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 1,279 trials mapped (456 active)	—	—	Biliary Tract Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07715903Phase 1 · not yet recruiting Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy · condition mapped ONTOLOGY_EXACT · 1,279 trials mapped (456 active)	—	—	Intrahepatic Cholangiocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06428409Phase 1/Phase 2 · recruiting A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) · condition mapped ALIAS · 1,279 trials mapped (456 active)	—	—	Malignant Biliary Tract Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06910670NA · active not recruiting Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid · condition mapped ONTOLOGY_EXACT · 1,279 trials mapped (456 active)	—	—	Cholangiocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07673341Phase 2 · recruiting [18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma · condition mapped ONTOLOGY_EXACT · 1,279 trials mapped (456 active)	—	—	Cholangiocarcinoma	1	Observed	clinicaltrials	graph →